Sunday, April 20, 2025

Yearly Archives: 2020

Best Use of Naukari Portal for Pharma Jobs

There are many job portals in India but Naukari.com covers 70 percents market share so you must upload your resume and details here. Many Freshers and...

Complete Guide for writing effective Pharma- Resume: Your First Impression

Resume is very important as it is the first opportunity of making an impression on the recruiter's mind. If you are skilled but do...

Complete Guide: How to Search and get the job in Pharma and CRO industry

Almost all Life Science students face the same problem: "How to Search and get the job in Pharma and CRO industry. In this blog, I...

FDA approves Life-changer for all childrens with peanut allergies

Jan 31, 2020: The first treatment for peanut allergies is about to hit the market, developed by Aimmune Therapeutics, a big step toward better...

WuXi Biologics gives Operation Update Related to the Coronavirus Outbreak

Jan 30, 2020: The coronavirus outbreak is having a potentially considerable social and economic impact in China.4 WuXi Biologics is directly monitoring the coronavirus outbreak and is complying with guidance from the relevant authorities....

The Best compilation of all job options in Pharmaceutical and CRO industries: Must read for freshers.

After graduation and post-graduation in life science(Bachelor in Pharmacy, Master in science or Pharmacy etc), students often find difficult to choose career/job options. I...

FDA Continues tough Support of Innovation in the Development of Gene Therapy Products

Jan 28, 2020: This is a pivotal time in the field of the gene therapy as the FDA continues its efforts in order to...

Clozaril, Fazaclo ODT, Versacloz (clozapine): Drug Safety Communication – FDA reinforce Warning That Untreated Constipation Can Lead to Serious Bowel Problems

Jan 28,2020: FDA is underpinning an existing warning that constipation caused by the schizophrenia medicine clozapine (Clozaril, Fazaclo ODT, Versacloz, generics) can, unusually, progress to serious bowel...

Phase II DESTINY-Gastric01 trial of Enhertu (trastuzumab deruxtecan) versus chemotherapy met primary endpoint

Jan 27, 2020: High-level results from the positive registrational Phase II trial DESTINY-Gastric01 showed AstraZeneca’s and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan),...

AstraZeneca’s Brilinta met primary endpoint in Phase III THALES trial in stroke

Jan 27, 2020: High-level results from the Phase III THALES trial showed AstraZeneca’s Brilinta (ticagrelor) 90 mg used daily two times a day and taken with...

FDA accepts for priority review Sanofi’s Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis

Jan 28, 2020: The U.S.FDA has accepted Priority Review the supplemental Biologics License Application (sBLA) for Sanofi’s Dupixent® (dupilumab) as an add-on maintenance treatment for...

AstraZeneca divests rights to Inderal, Tenormin, Tenoretic, Zestril and Zestoretic to Atnahs Pharma (Atnahs) to established hypertension medicines

Jan 27, 2020: AstraZeneca has decided to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination) to Atnahs Pharma (Atnahs). The...
- Advertisment -

Most Read